Japan· JP-6199001F1026
リファキシミン
A rifaximin product containing リファキシミン, registered in Japan by あすか製薬, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Rifaximin is registered in 14 of 19 countries.
Countries holding a registration under ATC A07AA11 (rifaximin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Rifaximin · ATC A07AA11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rifaximin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rifaximin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.02
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リファキシミン
- Manufacturer
- あすか製薬
- Country
- Japan (JP)
- ATC code
- A07AA11
- ATC class
- Rifaximin
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
88 interactions on record for rifaximin.
Graded by severity as the source publishes them — 63 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifaximin · interactions on record
88 records
- 63 moderate
- 25 info
Most severe, free to view
- RolapitantA04AD14moderate
- Sodium picosulfateA06AB08moderate
- EliglustatA16AX10moderate
- LonafarnibA16AX20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A07AA11
Rifaximin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3081d9d-803b-4327-a87d-2370f3ddf39c GET /v1/drugs/e3081d9d-803b-4327-a87d-2370f3ddf39c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6199001F1026",
"category": "内用薬",
"price_yen": 235.1,
"generic_name": "リファキシミン",
"product_name_jp": null,
"therapeutic_class": "6199",
"transitional_expiry": null
}See everything about rifaximin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.